// App-Quantinova.ai

: An engineered IL-2 partial agonist promotes CD8+ T cell stemness and anti-tumor efficacy (P216)

Researchers

Presenter

  • Fei Mo

Principal Investigators

  • Peng Li

  • Jangsuk Oh

  • Rosanne Spolski

  • Liang Zhao

  • Caleb R. Glassman

  • Tori N. Yamamoto

  • Yun Chen

  • Filip M. Golebiowski

  • Dalton Hermans

  • Sonia S. Marjri

  • Lora Picton

  • Wei Liao

  • Min Ren

  • Xiaoxuan Zhuang

  • Suman Mitra

  • Jian-Xin Lin

  • Luca Gattinoni

  • Jonathan D. Powell

  • Nicholas P. Restifo

  • K. Christopher Garcia

  • Warren J Leonard

Medical Centers

  • The Johns Hopkins University School of Medicine, MD.

  • Stanford University School of Medicine, San Francisco, California

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Melanoma

  • Solid malignancies

Biomarkers

  • Cluster of differentiation 8A

  • T-cell receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved